Major new investment announced to develop 2nd vaccine production site in Hungary >

Ceva continues to deliver double-digit growth >

Libourne 24th July 2017 - Consolidated sales of the Ceva Group reached €546m at the end of June 2017, representing growth of 20% versus last year and +6.6% at constant perimeter and exchange rates.

Ceva Phylaxia inaugurates state of the art vaccine plant to support “Innovation with Impact” growth plan >

Budapest, Hungary, July : Ceva Santé Animale, one of the fastest growing, top 10 animal healthcare companies today held the inauguration ceremony of its new European vaccine production facility

Ceva reinforces its position in china and swine through new joint-venture with EBVAC >

In the presence of the Chinese Prime Minister, Li Keqiang and French Prime Minister, Bernard Cazeneuve, Ceva Santé Animale (Ceva) and EBVAC today signed a joint-venture agreement to create a new business, Ceva EBVAC, focused on the swine sector.

Ceva Santé Animale confirms its circle of virtuous growth in 2016 >

2016 was a year of sustained organic growth and major acquisitions. Consolidated sales reached €912m as the Ceva Group continued to achieve double-digit growth, cementing its position as the 6th. largest animal health company.

Ceva stresses the need for continued innovation to ensure effective disease control at IPPE 2017 >

Vectormune® ND, vaccine for Newcastle Disease (ND) Cevac IBird®, for Infectious Bronchitis (IB) prevention will continue to lead offerings for effective and easily administered disease control.

Launch of the WVPA-Ceva joint digital library >

Launch of a digital library resource on poultry veterinary medicine

Ceva completes deal to acquire portfolio of Merial swine & cattle vaccines and nonsteroidal anti-inflammatories from Boehringer Ingelheim >

19 January 2017: Ceva Santé Animale today completed the acquisition of a diversified portfolio of products, including swine and cattle vaccines and multi-species nonsteroidal anti-inflammatories from Boehringer Ingelheim .

Ceva acquires Hertape and Inova to enter brazil’s top 5 animal health companies >

Move will increase the group global vaccine footprint with significant entry into the ruminant, Foot and Mouth disease market and a first entry into companion animal vaccines.

C.H.I.C.K Program receives the 1st independently audited quality recognition >

For the first time, an AH company services program receives internationally recognized quality approval from Bureau Veritas.